Pathogenesis of Chronic Chagasic Myocarditis

González, Julián; Azzato, Francisco; Ambrosio, Giusepe; Milei, José

doi:10.5772/55387

Cited by 1 publication

(1 citation statement)

References 145 publications

(146 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All sera were tested using two commercial kits selected accordingly Santos et al (2016). The antigen sequences were selected from the literature using their previous use in ELISA as inclusion criteria, radioimmunoprecipitation assay (RIPA), or lateral flow tests of populations from different regions [ 22 – 24 ], subcellular localization (cytoskeleton and membrane associated, cytoplasmic and shed proteins) [ 25 , 26 ], tandem repeats, presence in chronic infective phase [ 27 , 28 ], low cross-reactivity with other protozoans [ 29 – 31 ], among other criteria.…”

Section: Introductionmentioning

confidence: 99%

Performance Assessment of Four Chimeric Trypanosoma cruzi Antigens Based on Antigen-Antibody Detection for Diagnosis of Chronic Chagas Disease

Santos¹,

Celedón²,

Zanchin³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

The performance of serologic tests in chronic Chagas disease diagnosis largely depends on the type and quality of the antigen preparations that are used for detection of anti-Trypanosoma cruzi antibodies. Whole-cell T. cruzi extracts or recombinant proteins have shown variation in the performance and cross-reactivity. Synthetic chimeric proteins comprising fragments of repetitive amino acids of several different proteins have been shown to improve assay performances to detect Chagasic infections. Here, we describe the production of four chimeric T. cruzi proteins and the assessment of their performance for diagnostic purposes. Circular Dichroism spectra indicated the absence of well-defined secondary structures, while polydispersity evaluated by Dynamic Light Scattering revealed only minor aggregates in 50 mM carbonate-bicarbonate (pH 9.6), demonstrating that it is an appropriate buffering system for sensitizing microplates. Serum samples from T. cruzi-infected and non-infected individuals were used to assess the performance of these antigens for detecting antibodies against T. cruzi, using both enzyme-linked immunosorbent assay and a liquid bead array platform. Performance parameters (AUC, sensitivity, specificity, accuracy and J index) showed high diagnostic accuracy for all chimeric proteins for detection of specific anti-T. cruzi antibodies and differentiated seropositive individuals from those who were seronegative. Our data suggest that these four chimeric proteins are eligible for phase II studies.

show abstract